Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

15.34
-0.2400-1.54%
Post-market: 15.340.00000.00%19:35 EDT
Volume:1.19M
Turnover:18.38M
Market Cap:1.21B
PE:7.56
High:15.86
Open:15.58
Low:15.24
Close:15.58
52wk High:16.77
52wk Low:5.70
Shares:78.65M
Float Shares:70.64M
Volume Ratio:0.59
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:5.20
PE(LYR):8.20

Loading ...

PagerDuty Executive Chair Jennifer Tejada Disposes of USD 1,617,748 in Common Shares

Reuters
·
Yesterday

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

GlobeNewswire
·
Oct 02

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

GlobeNewswire
·
Sep 29

Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial

GlobeNewswire
·
Sep 16

Hong Kong Stock Alert | LEADS BIOLABS-B (09887) Opens Nearly 3% Higher as PD-L1/4-1BB Bispecific Antibody Achieves Dual Breakthroughs in Response Rate and PFS Rate for First-Line NSCLC Treatment

Stock News
·
Sep 15

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid

GlobeNewswire
·
Sep 15

Boan Biotech Wins CDE IND Nod for Novel PD-1/IL-2 Cancer Drug BA1203

TIPRANKS
·
Sep 14

LEADS BIOLABS-B (09887) Presents Updated Phase II Data on Vilixine® (Oritasomimab, PD-L1/4-1BB Bispecific) Combined with Chemotherapy as First-Line NSCLC Treatment at WCLC 2026 Oral Session

Stock News
·
Sep 14

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

GlobeNewswire
·
Sep 09

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

GlobeNewswire
·
Sep 09

Supernus Pharmaceuticals to Participate in September Investor Conferences

GlobeNewswire
·
Sep 03

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

GlobeNewswire
·
Aug 31

PagerDuty Reports 'Decent' Q2, Cuts Workforce to Drive Growth, RBC Capital Markets Says

MT Newswires Live
·
Aug 28

PagerDuty Price Target Raised to $15.00/Share from $10.00 by Canaccord Genuity

Dow Jones
·
Aug 28

Truist Financial Remains a Buy on PagerDuty (PD)

TIPRANKS
·
Aug 28

Truist Raises Price Target on PagerDuty to $15 From $13, Keeps Buy Rating

MT Newswires Live
·
Aug 28

Analysts Offer Insights on Technology Companies: Autodesk (ADSK), Workday (WDAY) and PagerDuty (PD)

TIPRANKS
·
Aug 28

PagerDuty price target raised to $10 from $9 at Morgan Stanley

TIPRANKS
·
Aug 28

PagerDuty, Inc. Reports Results for the Quarter Ended July 31 - Earnings Summary

Reuters
·
Aug 28

Pagerduty - Announces Headcount Reduction of About 15% - SEC Filing

Reuters
·
Aug 28